Proprietary AI analyst is now available

908 Devices Valuation Multiples

Discover 908 Devices' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Abbott Pakistan, Perspective Therapeutics, CapsoVision, Advanced Technology Company and more.

908 Devices Overview

About 908 Devices

908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.


Founded

2012

HQ

United States

Employees

71

Financials (LTM)

Revenue: $62M
EBITDA: ($8M)

EV

$227M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

908 Devices Financials

908 Devices reported last 12-month revenue of $62M and negative EBITDA of ($8M).

In the same LTM period, 908 Devices generated $34M in gross profit, ($8M) in EBITDA losses, and had net loss of ($26M).

Revenue (LTM)


908 Devices P&L

In the most recent fiscal year, 908 Devices reported revenue of $56M and EBITDA of ($10M).

908 Devices is profitable as of last fiscal year, with gross margin of 51%, EBITDA margin of (17%), and net margin of 35%.

See analyst estimates for 908 Devices
LTMLast FY202320242025202620272028
Revenue$62M$56M$50M$60M$56M
Gross Profit$34M$28M$25M$30M$28M
Gross Margin54%51%50%50%51%
EBITDA($8M)($10M)($34M)($68M)($21M)
EBITDA Margin(13%)(17%)(68%)(114%)(38%)
EBIT Margin(28%)(27%)(85%)(83%)(46%)
Net Profit($26M)$19M($36M)($72M)$19M
Net Margin(43%)35%(72%)(121%)35%

Financial data powered by Morningstar, Inc.

908 Devices Stock Performance

908 Devices has current market cap of $335M, and enterprise value of $227M.

Market Cap Evolution


908 Devices' stock price is $8.85.

908 Devices share price increased by 4.9% in the last 30 days, and by 24.8% in the last year.

908 Devices has an EPS (earnings per share) of $0.52.

See more trading valuation data for 908 Devices
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$227M$335M0.0%4.9%44.6%24.8%$0.52

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

908 Devices Valuation Multiples

908 Devices trades at 3.7x EV/Revenue multiple, and (28.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for 908 Devices

EV / Revenue (LTM)


908 Devices Financial Valuation Multiples

As of June 22, 2026, 908 Devices has market cap of $335M and EV of $227M.

908 Devices has a P/E ratio of (12.7x).

LTMLast FY202320242025202620272028
EV/Revenue3.7x4.0x4.5x3.8x4.0x
EV/EBITDA(28.8x)(23.7x)(6.7x)(3.4x)(10.7x)
EV/EBIT(13.1x)(14.8x)(5.3x)(4.6x)(8.9x)
EV/Gross Profit6.8x8.0x9.0x7.6x8.0x
P/E(12.7x)17.2x(9.2x)(4.6x)17.2x
EV/FCF(10.3x)(10.3x)(8.4x)(7.4x)(9.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified 908 Devices Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

908 Devices Margins & Growth Rates

908 Devices grew revenue by 22% but EBITDA decreased by 37% in the last fiscal year.

In the most recent fiscal year, 908 Devices reported gross margin of 51%, EBITDA margin of (17%), and net margin of 35%.

See estimated margins and future growth rates for 908 Devices

908 Devices Margins

Last FY202420252026202720282029
Gross Margin51%50%51%55%
EBITDA Margin(17%)(114%)(38%)(9%)
EBIT Margin(27%)(83%)(46%)(28%)
Net Margin35%(121%)35%(27%)
FCF Margin(39%)(52%)(44%)-

908 Devices Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth22%19%(6%)22%
Gross Profit Growth32%18%(5%)32%
EBITDA Growth(37%)99%(69%)(72%)
EBIT Growth26%15%(48%)(24%)
Net Profit Growth(196%)98%(127%)(196%)
FCF Growth-14%(20%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

908 Devices Operational KPIs

908 Devices' revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.8M for the same period.

908 Devices' Rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

908 Devices' Rule of X is 46% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for 908 Devices
LTMLast FY202320242025202620272028
Rule of 408%13%---
Bessemer Rule of X40%46%---
Revenue per Employee-$0.8M---
Opex per Employee-$0.8M---
R&D Expenses to Revenue25%28%44%43%28%
Opex to Revenue-96%136%133%96%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Abbott Pakistan1.1x-5.3x-
Perspective Therapeutics78.9x106.8x(0.7x)(0.6x)
CapsoVision23.1x21.6x(12.6x)-
Advanced Technology Company1.9x-147.6x-
CellaVision3.8x3.8x11.9x12.3x
Standard BioTools(1.2x)(1.2x)1.6x2.5x
NIOX Group4.6x4.5x13.3x13.0x
SmartVest4.7x4.1x21.7x17.5x

This data is available for Pro users. Sign up to see all 908 Devices competitors and their valuation data.

Start Free Trial

908 Devices VC Funding History

Before going public, 908 Devices raised $56M in total equity funding, across 4 rounds.


908 Devices Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Apr-19Series ETao Capital Partners; Northpond Ventures; Casdin Capital; Sands Capital Ventures; Razor's Edge Ventures; ArchVentures SA; SLB; Saudi Aramco Energy Ventures$18M-908 Devices closed a $17.5 million Series E growth equity funding round on April 29, 2019, led by Northpond Ventures with participation from Sands Capital Ventures, ARCH Ventures, Razor’s Edge Ventures, Saudi Aramco Energy Ventures, Schlumberger, Tao Capital Partners, and Casdin Capital. This brought the company's total funding to $70 million. Northpond Ventures' Sharon Kedar joined the board. The funds were allocated to deepen application support and broaden capabilities for MX908 and ZipChip product lines, and accelerate development of additional tools including a new life science device. 908 Devices develops analytical devices for chemical and biomolecular analysis, positioning it as a leader in the multibillion-dollar mass spectrometry market with products adopted in life science and field forensic markets.
Mar-17Series DTao Capital Partners; Casdin Capital; Razor's Edge Ventures; SLB; Saudi Aramco Energy Ventures; Cormorant Asset Management; ARCH Venture Partners$20M-908 Devices is a pioneer of analytical devices for chemical and biomolecular analysis, developing handheld and desktop mass spectrometer devices that analyze the chemical makeup of materials and substances. Founded in 2012, the company's product platform has broad commercial applications in security, biotechnology, and other markets. On March 21, 2017, 908 Devices closed a $20 million Growth funding round led by Tao Capital Partners, with participation from ARCH Venture Partners, Casdin Capital, Cormorant Asset Management, Razor's Edge Ventures, Saudi Aramco Energy Ventures, Schlumberger Technology Investments, and other investors. The capital was intended to support product development and market expansion. The company went on to secure an additional $17.5 million in Series E funding in April 2019, bringing total pre-IPO funding to $70 million. 908 Devices subsequently completed its initial public offering in December 2020, raising approximately $150 million at $20 per share.
May-15Series CUTEC-The University of Tokyo Edge Capital Partners; Razor's Edge Ventures; SLB; Saudi Aramco Energy Ventures; ARCH Venture Partners$12M-908 Devices, a US-based producer of analytical devices for chemical analysis, closed an $11.6 million Series C funding round in mid-2015 led by Saudi Aramco Energy Ventures. Investors included Schlumberger, Arch Venture Partners, Razor’s Edge Ventures, and University of Tokyo Edge Capital Partners (UTEC). The round brought the company's total funding to $27.6 million, following a $7 million Series B in 2013 from some of the same investors and earlier backing from In-Q-Tel. The company manufactures handheld chemical detection tools and footprint analyzers for researchers based on high-pressure mass spectrometry (HPMS) technology. Funding supported development of additional products for safety and security, oil and gas, environmental, and life science industries. Saudi Aramco recognized the technology's potential for petroleum and petrochemical operations, enabling analysis at the point of need. 908 Devices continued raising capital in subsequent rounds, including a $20 million round in 2017 led by Tao Capital Partners with participation from Saudi Aramco Energy Ventures and Schlumberger, increasing total funding to about $47.6 million, and a $17.5 million Series E in 2019 bringing the total to $70 million.
Aug-13Series BUTEC-The University of Tokyo Edge Capital Partners; Razor's Edge Ventures; SLB; ARCH Venture Partners$7M--

Acquisitions by 908 Devices

908 Devices has acquired 3 companies to date.

Last acquisition by 908 Devices was on May 5th 2026. 908 Devices acquired NIRLAB for $15M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by 908 Devices

NIRLAB
RedWave Technology
TRACE Analytics
Description
NIRLAB is a Swiss company and University of Lausanne spin-off that delivers real-time material analysis using AI and near-infrared spectroscopy for industries including pharmaceuticals, agriculture, food, and recycling across more than 30 countries.
RedWave Technology is a provider of portable Fourier Transform Infrared spectrometers for material identification and chemical analysis. The battery-powered devices perform non-destructive testing in hazmat response, forensics, and industrial quality control. RedWave Technology, based in the United States, supplies units to emergency responders and laboratories worldwide.
TRACE Analytics is a German company offering online analysis systems for biopharmaceutical applications. Located in Munich, it provides measurement technologies for gas, liquid, and multiphase flows in research labs, pilot plants, and production facilities. The systems support process analytical technology in biotech fermentation, cell culture monitoring, and downstream processing for vaccine and monoclonal antibody manufacturing.
HQ CountrySwitzerlandUnited StatesGermany
HQ City
Lausanne
Danbury, CT
Braunschweig
Deal Date5 May 202630 Apr 20249 Aug 2022
Valuation$15M$54M$15M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all 908 Devices acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About 908 Devices

When was 908 Devices founded?908 Devices was founded in 2012.
Where is 908 Devices headquartered?908 Devices is headquartered in United States.
How many employees does 908 Devices have?As of today, 908 Devices has over 71 employees.
Who is the CEO of 908 Devices?908 Devices' CEO is Kevin J. Knopp.
Is 908 Devices publicly listed?Yes, 908 Devices is a public company listed on Nasdaq.
What is the stock symbol of 908 Devices?908 Devices trades under MASS ticker.
When did 908 Devices go public?908 Devices went public in 2020.
Who are competitors of 908 Devices?908 Devices main competitors include Abbott Pakistan, Perspective Therapeutics, CapsoVision, Advanced Technology Company, CellaVision, Standard BioTools, NIOX Group, SmartVest, Senseonics Holdings, Universal Vision.
What is the current market cap of 908 Devices?908 Devices' current market cap is $335M.
What is the current revenue of 908 Devices?908 Devices' last 12 months revenue is $62M.
What is the current revenue growth of 908 Devices?908 Devices revenue growth (NTM/LTM) is 21%.
What is the current EV/Revenue multiple of 908 Devices?Current revenue multiple of 908 Devices is 3.7x.
Is 908 Devices profitable?No, 908 Devices is not profitable.
What is the current EBITDA of 908 Devices?908 Devices has negative EBITDA and is not profitable.
What is 908 Devices' EBITDA margin?908 Devices' last 12 months EBITDA margin is (13%).
What is the current EV/EBITDA multiple of 908 Devices?Current EBITDA multiple of 908 Devices is (28.8x).
What is the current FCF of 908 Devices?908 Devices' last 12 months FCF is ($22M).
What is 908 Devices' FCF margin?908 Devices' last 12 months FCF margin is (35%).
What is the current EV/FCF multiple of 908 Devices?Current FCF multiple of 908 Devices is (10.3x).
How many companies 908 Devices has acquired to date?As of June 2026, 908 Devices has acquired 3 companies.
What was the largest acquisition by 908 Devices?$54M acquisition of RedWave Technology on 30th April 2024 was the largest M&A 908 Devices has done to date.
What companies 908 Devices acquired?908 Devices acquired RedWave Technology, TRACE Analytics, and NIRLAB.
In how many companies 908 Devices has invested to date?908 Devices hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to 908 Devices

Lists including 908 Devices

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial